Tratamiento sistémico para el cáncer de mama HER2 positivo avanzado. Revisión de la evidencia y abordaje terapéutico en el Instituto Nacional de Cancerología - Colombia

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660

Martínez-Sáez O, Prat A. Current and future management of HER2-positive metastatic breast cancer. JCO Oncol Pract. 2021; OP.21.00172. https://doi.org/10.1200/OP.21.00172

Díaz‐Casas SE, Castilla‐Tarra JA, Pena‐Torres E, Orozco‐Ospino M, Mendoza‐Diaz S, Nuñez‐Lemus M, et al. Pathological response to neoadjuvant chemotherapy and the molecular classification of locally advanced breast cancer in a Latin American cohort. Oncologist. 2019;24(12):1360–70. https://doi.org/10.1634/theoncologist.2019-0300

Collins DM, Madden SF, Gaynor N, AlSultan D, Le Gal M, Eustace AJ, et al. Effects of HER family-targeting tyrosine kinase inhibitors on antibody-dependent cell-mediated cytotoxicity in HER2-expressing breast cancer. Clin Cancer Res. 2021;27(3):807–18. https://doi.org/10.1158/1078-0432.CCR-20-2007

Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, et al. 5th ESO-ESMO International consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623–49. https://doi.org/10.1016/j.annonc.2020.09.010

Slamon, DJ, Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde A et al. Use of chemotherapy plus a monoclonal antibody against HER2. 2001;344(11):783–92. https://doi.org/10.1056/NEJM200103153441101

Salkeni MA, Rizvi W, Hein K, Higa GM. Neu perspectives, therapies, and challenges for metastatic HER2-positive breast cancer. Breast Cancer Targets Ther. 2021;13(June):539–57. https://doi.org/10.2147/BCTT.S288344

Krop IE, Lin NU, Blackwell K, Guardino E, Huober J, Lu M, et al. Annals of oncology advance access published October 29 , 2014. Ann Oncol. 2014;1–15. https://doi.org/10.1093/annonc/mdu486

Lambertini M, Vaz-Luis I. Is HER2-positive metastatic breast cancer still an incurable disease? Lancet Oncol. 2020;21(4):471–2. http://dx.doi.org/10.1016/S1470-2045(20)30058-9

Valabrega G, Montemurro F, Aglietta M. Trastuzumab: Mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol. 2007;18(6):977–84. https://doi.org/10.1093/annonc/mdl475

Swain SM, Sung-Bae Kim, Cortés J, Jungsil Ro, Semiglazov V, Campone, M et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, doubleblind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14(6):461–71. https://doi.org/10.1016/S1470-2045(13)70130-X

Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): End-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(4):519–30. https://doi.org/10.1016/S1470-2045(19)30863-0

Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, et al. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Ann Oncol. 2019;30(5):766–73. https://doi.org/10.1093/annonc/mdz061

Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, et al. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. Ann Oncol. 2021. https://doi.org/10.1016/j.annonc.2021.06.024

Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized phase III TAnDEM study. J Clin Oncol. 2009;27(33):5529–37. https://doi.org/10.1200/JCO.2008.20.6847

Huober J, Fasching PA, Barsoum M, Petruzelka L, Wallwiener D, Thomssen C, et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormonereceptor-positive metastatic breast cancer - Results of the eLEcTRA trial. Breast. 2012;21(1):27–33. http://dx.doi.org/10.1016/j.breast.2011.07.006

Rimawi M, Ferrero JM, De La Haba-Rodriguez J, Poole C, De Placido S, Osborne CK, et al. First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): A randomized, open-label phase II trial. J Clin Oncol. 2018;36(28):2826–35. https://doi.org/10.1200/JCO.2017.76.7863

Targeted Oncology, SABCS 2020: PERTAIN updates in HER2+, HR+ MBC. HER2+ BC: A year in review and updates from SABCS - Episode 9. Available from: https://www.targetedonc.com/view/sabcs-2020-pertain-updates-in-her2-hr-mbc

Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2- positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–91. https://doi.org/10.1056/NEJMoa1209124

Diéras V, Miles D, Verma S, Pegram M, Welslau M, Baselga J, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(6):732–42. https://doi.org/10.1016/S1470-2045(17)30312-1

Krop IE, Kim SB, Martin AG, LoRusso PM, Ferrero JM, Badovinac-Crnjevic T, et al. Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): Final overall survival results from a randomised open-label phase 3 trial Lancet Oncol. 2017;18(6):743–54. https://doi.org/10.1016/s1470-2045(17)30313-3

Modi S, Saura C, Yamashita T, Park YH, Kim S-B, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610–21. https://doi.org/10.1056/NEJMoa1914510

Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: Final results from the EGF104900 study. J Clin Oncol. 2012;30(21):2585–92. https://doi.org/10.1200/JCO.2011.35.6725

Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008;112(3):533–43. https://doi.org/10.1007/s10549-007-9885-0

Cameron D, Casey M, Oliva C, Newstat B, Imwalle B, Geyer CE. Lapatinib plus capecitabine in women with HER‐2–positive advanced breast cancer: Final survival analysis of a phase iii randomized trial. Oncologist. 2010;15(9):924–34.https://doi.org/10.1634/theoncologist.2009-0181

Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597–609. https://doi.org/10.1056/NEJMoa1914609

Saura C, Oliveira M, Feng YH, Dai MS, Chen SW, Hurvitz SA, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Phase III NALA trial. J Clin Oncol. 2020;38(27):3138–49. https://doi.org/10.1200/JCO.20.00147

Valabrega G, Montemurro F, Aglietta M. Trastuzumab: Mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol. 2007;18(6):977–84. https://doi.org/10.1093/annonc/mdl475

Chia S, Clemons M, Martin LA, Rodgers A, Gelmon K, Pond GR, Panasci L. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: A multicenter phase II trial. J Clin Oncol. 2006;24(18):2773-8. https://doi.org/10.1200/JCO.2005.03.8331